Vertex Gears Up For Next Generation In CF Therapy

Orkambi posts sales of $131m in its first quarter on the market, reaching 35% of CF patients eligible for therapy under its label. Firm also updated investors on plans for next-generation CF drugs

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from United States

More from North America